Corticosteroid use in neurocysticercosis
- PMID: 21797658
- PMCID: PMC3721198
- DOI: 10.1586/ern.11.86
Corticosteroid use in neurocysticercosis
Abstract
The cystic larvae of Taenia solium commonly infect the human nervous system, resulting in neurocysticercosis, a major contributor to seizure disorders in most of the world. Inflammation around the parasites is a hallmark of neurocysticercosis pathophysiology. Although mechanisms regulating this inflammation are poorly understood, anti-inflammatory drugs, particularly corticosteroids, have been long used alone or with anthelmintics to manage disease and limit neurological complications and perhaps damage to neural tissues. Only scarce controlled data exist to determine when and what type of corticosteroids and the treatment regime to use. This article revisits the mechanisms of action, rationale, evidence of benefit, safety and problems of corticosteroids in the context of neurocysticercosis, as well as alternative anti-inflammatory strategies to limit the damage caused by inflammation in the CNS.
Figures
References
-
- Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 2005;4(10):653–661. - PubMed
-
- Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol. 1994;4:77–116. - PubMed
-
- Mahanty S, Garcia HH. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol. 2010;91(2):172–184. - PubMed
-
- Lobato RD, Lamas E, Portillo JM, et al. Hydrocephalus in cerebral cysticercosis Pathogenic and therapeutic considerations. J Neurosurg. 1981;55(5):786–793. - PubMed
-
- Bickerstaff ER, Cloake PCP, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain. 1952;75:1–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical